Axsome Therapeutics
Stock Forecast, Prediction & Price Target

Axsome Therapeutics (AXSM) stock Price Target by analysts

Last Year
Average Price Target

$127

Potential upside: 13.39%

Based on 3 analysts

Axsome Therapeutics price prediction

Strike.market

What is Axsome Therapeutics stock analysts` prediction?

Axsome Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Axsome Therapeutics in the last 3 months, the avarage price target is $127, with a high forecast of $NaN. The average price target represents a 13.39% change from the last price of $112.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Axsome Therapeutics stock Price Target by analysts

Full breakdown of analysts given Axsome Therapeutics price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Yatin Suneja
Guggenheim
0%
0/1
10 months ago $135 20.53% upside $99.49 StreetInsider
Previous targets (0)
Graig Suvannavejh
Mizuho Securities
0%
0/2
12 months ago $106 -5.35% downside $90.58 StreetInsider
Previous targets (1)
Cerena Chen
Wells Fargo
0%
0/1
12 months ago $140 25% upside $88.86 TheFly
Previous targets (0)
Jason Gerberry
Bank of America Securities
0%
0/1
about 1 year ago $106 -5.35% downside $83.93 StreetInsider
Previous targets (0)
Raghuram Selvaraju
H.C. Wainwright
0%
0/1
about 1 year ago $180 60.71% upside $83.21 TheFly
Previous targets (0)
Leonid Timashev
RBC Capital
0%
0/2
about 1 year ago $131 16.96% upside $84.85 StreetInsider
Previous targets (1)
Leonid Timashev
RBC Capital
0%
0/2
about 1 year ago $130 16.07% upside $72.24 StreetInsider
Previous targets (1)
David Amsellem
Piper Sandler
0%
0/1
over 1 year ago $115 2.67% upside $75.19 StreetInsider
Previous targets (0)
Vikram Purohit
Morgan Stanley
0%
0/1
over 1 year ago $115 2.67% upside $74.14 StreetInsider
Previous targets (0)
Graig Suvannavejh
Mizuho Securities
0%
0/2
over 1 year ago $109 -2.67% downside $79.17 StreetInsider
Previous targets (1)
Joel Beatty
Robert W. Baird
0%
0/1
over 1 year ago $108 -3.57% downside $72.54 StreetInsider
Previous targets (0)
Unknown
Piper Sandler
N/A
over 2 years ago $75 -33.03% downside $73.34 Benzinga
N/A
Robert Hazlett
BTIG
0%
0/1
over 2 years ago $98 -12.5% downside $75.13 TheFly
Previous targets (0)
Unknown
Morgan Stanley
N/A
almost 3 years ago $86 -23.21% downside $74.95 Benzinga
N/A
Unknown
Leerink Partners
N/A
almost 3 years ago $85 -24.10% downside $74.74 Benzinga
N/A
Unknown
Guggenheim
N/A
almost 3 years ago $80 -28.57% downside $55.49 Benzinga
N/A
Joon Lee
Truist Financial
0%
0/2
about 3 years ago $150 33.92% upside $59.03 TheFly
Previous targets (1)
Unknown
Mizuho Securities
N/A
over 3 years ago $49 -56.25% downside $34.04 Benzinga
N/A
Unknown
Morgan Stanley
N/A
over 3 years ago $27 -75.89% downside $30.59 Benzinga
N/A
Joon Lee
Truist Financial
0%
0/2
over 3 years ago $90 -19.64% downside $30.98 Pulse 2.0
Previous targets (1)
Ashwani Verma
Bank of America Securities
100%
1/1
about 4 years ago $25 -77.67% downside $23.78 StreetInsider
Previous targets (0)

Axsome Therapeutics Financial Estimates

Axsome Therapeutics Revenue Estimates

Axsome Therapeutics EBITDA Estimates

Axsome Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$0
 
N/A
$50.03M
 
0%
$270.6M
 
440.79%
Avg: $671.48M
Low: $493.50M
High: $778.84M
avg. 148.14%
Avg: $1.11B
Low: $888.85M
High: $1.33B
avg. 66.17%
Avg: $1.56B
Low: $1.24B
High: $1.86B
avg. 40.04%
Avg: $2.04B
Low: $1.62B
High: $2.43B
avg. 30.55%
Net Income
 
% change YoY
$-134.94M
 
N/A
$-197.76M
 
-46.55%
$-239.23M
 
-20.96%
Avg: $-16.45M
Low: $-180.79M
High: $154.44M
avg. 93.12%
Avg: $323.72M
Low: $8.63M
High: $626.86M
avg. 2067.37%
Avg: $556.58M
Low: $409.38M
High: $696.33M
avg. 71.93%
Avg: $758.34M
Low: $557.77M
High: $948.73M
avg. 36.24%
EBITDA
 
% change YoY
$-124.70M
 
N/A
$-170.93M
 
-37.07%
$-224.99M
 
-31.62%
Avg: $181.21M
Low: $133.17M
High: $210.18M
avg. 180.54%
Avg: $301.13M
Low: $239.86M
High: $359.29M
avg. 66.17%
Avg: $421.72M
Low: $335.92M
High: $503.17M
avg. 40.04%
Avg: $550.60M
Low: $438.58M
High: $656.93M
avg. 30.55%
EPS
 
% change YoY
-$3.59
 
N/A
-$4.86
 
-35.37%
-$5.27
 
-8.43%
Avg: -$0.23
Low: -$3.98
High: $3.4
avg. 95.71%
Avg: $6.4
Low: $0.19
High: $13.8
avg. 2933.81%
Avg: $12.25
Low: $9.01
High: $15.33
avg. 91.46%
Avg: $16.69
Low: $12.28
High: $20.89
avg. 36.24%
Operating Expenses
 
% change YoY
$124.70M
 
N/A
$221.34M
 
77.48%
$476.36M
 
115.21%
Avg: $990.68M
Low: $728.09M
High: $1.14B
avg. 107.96%
Avg: $1.64B
Low: $1.31B
High: $1.96B
avg. 66.17%
Avg: $2.30B
Low: $1.83B
High: $2.75B
avg. 40.04%
Avg: $3.01B
Low: $2.39B
High: $3.59B
avg. 30.55%

FAQ

What is Axsome Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 567.16% in 2025-2028.

We have gathered data from 12 analysts. Their low estimate is -180.79M, average is -16.45M and high is 154.44M.

What is Axsome Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 71.23% in 2025-2028.

We have gathered data from 13 analysts. Their low revenue estimate is $493.50M, average is $671.48M and high is $778.84M.

What is Axsome Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 789.30% in 2025-2028.

We have gathered data from 12 analysts. Their low earnings per share estimate is -$3.98, average is -$0.23 and high is $3.4.

What is the best performing analyst?

In the last twelve months 3 analysts have been covering Axsome Therapeutics stock. The most successful analyst is Yatin Suneja.